Skip to main content

Table 7 HDL-C

From: Comparative efficacy of pharmacological interventions on metabolic and hormonal outcomes in polycystic ovary syndrome: a Network Meta-Analysis of Randomized controlled trials

Orlistat

        

0.07 (−1.80,1.94)

Standard + Dpp4

       

0.27 (−1.02,1.56)

0.20 (−1.73,2.13)

Standard + Flutamide

      

0.68 (−0.21,1.57)

0.61 (−1.03,2.25)

0.41 (−0.60,1.42)

Standard

     

0.67 (−0.73,2.07)

0.60 (−1.37,2.56)

0.40 (−1.08,1.88)

−0.01 (−1.09,1.07)

Sglt-2

    

0.91 (−0.38,2.20)

0.84 (−1.09,2.77)

0.64 (−0.48,1.77)

0.23 (−0.78,1.24)

0.24 (−1.24,1.72)

Flutamide

   

0.90 (0.02,1.79)

0.83 (−0.89,2.56)

0.64 (−0.37,1.65)

0.23 (−0.30,0.75)

0.24 (−0.97,1.44)

−0.01 (−1.01,1.00)

Placebo

  

1.22 (−0.08,2.51)

1.15 (−0.76,3.05)

0.95 (−0.43,2.33)

0.54 (−0.42,1.50)

0.55 (−0.90,1.99)

0.31 (−1.07,1.69)

0.31 (−0.75,1.38)

Standard + Glp-1

 

1.29 (0.18,2.41)

1.22 (−0.56,3.01)

1.03 (−0.18,2.24)

0.62 (−0.09,1.32)

0.63 (−0.66,1.91)

0.38 (−0.82,1.59)

0.39 (−0.43,1.21)

0.08 (−0.81,0.96)

Glp-1